US EditionFDA Approves Combo of Opdivo Plus Yervoy for Advanced Liver Cancer
- The FDA granted full approval for Opdivo plus Yervoy to treat advanced liver cancer.
- This approval expands the indication into first-line treatment based on CheckMate-9DW trial results.
- The CheckMate-9DW trial involved 335 participants treated with Opdivo plus Yervoy.
- Aiwu Ruth He stated the approval marks an important advancement, noting poor HCC prognosis.
- Results showed a 38% survival rate at three years with the combination therapy.
Insights by Ground AI
Does this summary seem wrong?
42 Articles
42 Articles
All
Left
6
Center
12
Right
9
FDA Approves Combo of Opdivo Plus Yervoy for Advanced Liver Cancer
TUESDAY, April 15, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment for adults with unresectable or metastatic hepatocellular carcinoma (HCC).
Coverage Details
Total News Sources42
Leaning Left6Leaning Right9Center12Last UpdatedBias Distribution44% Center
Bias Distribution
- 44% of the sources are Center
44% Center
L 22%
C 44%
R 33%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
